The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of patients with multiple primary tumors.
 
Karen Anne Cadoo
Honoraria - OncLive
Consulting or Advisory Role - GlaxoSmithKline/Tesaro
Research Funding - AstraZeneca (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Semanti Mukherjee
Stock and Other Ownership Interests - Regeneron
 
Aliya Khurram
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Kaitlyn Tkachuk
No Relationships to Disclose
 
Ying L Liu
No Relationships to Disclose
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Michael Francis Walsh
No Relationships to Disclose
 
Alicia Latham
Other Relationship - Conquer Cancer Foundation
 
Marianne E Dubard-Gault
Stock and Other Ownership Interests - Illumina (I)
 
Diana Mandelker
No Relationships to Disclose
 
Yuhan Wang
No Relationships to Disclose
 
Erin E. Salo-Mullen
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Grail
 
Vignesh Ravichandran
No Relationships to Disclose
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Alimera Sciences (I); Allergan (I); Biomarin (I); Fortress Biotech (I); Genentech/Roche (I); Novartis (I); Optos (I); Regeneron (I); Regenxbio (I); Spark Therapeutics (I)
 
Vijai Joseph
Patents, Royalties, Other Intellectual Property - Title: DIAGNOSIS & TREATMENT OF ERCC3-MUTANT CANCER Inventors: Vijai Joseph, Sabine Topka, Kenneth Offit US National Stage Patent Application No.: 16/493,214 Filing Date: September 11, 2019 (Inst)
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - Change HealthCare
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Clinical Care Options; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Merck; Pfizer
 
Venkatraman E. Seshan
No Relationships to Disclose
 
Kenneth Offit
No Relationships to Disclose